Abstract 5901
Background
Cabozantinib (C) is an inhibitor of multiple receptor tyrosine kinases involved in tumor cell proliferation, neovascularization, and immune cell regulation, including MET, VEGFRs, and TAM family of kinases (TYRO3, MER, and AXL). Preclinical/clinical studies suggest that C promotes an immune-permissive environment that may facilitate synergistic effects with checkpoint inhibitors. This Phase 1b study evaluates C in combination with the programmed death ligand (PD-L1) targeting antibody atezolizumab (A) in pts with solid tumors (NCT03170960).
Methods
Safety and clinical activity of C (2 dose levels: 40 mg, 60 mg QD) + A (1200 mg Q3W) administered in 3-week cycles were evaluated in a 3 + 3 dose escalation design. Safety data of all pts and criteria for dose limiting toxicity (DLT) determined the recommended dose (RD) for a subsequent expansion stage. Tumor response was assessed by CT/MRI and bone scan (RECIST v 1.1).
Results
12 pts with treatment-naïve advanced RCC (mostly clear-cell subtype) were treated in the dose escalation stage (6 at each dose level). At data cutoff, all pts were actively receiving study treatment (range, 3–12 cycles). There were no DLTs or serious adverse events (AEs) in either C+A dose cohort. Most AEs were Grade 1/2 including immune-related AEs. Grade 3 AEs included 3 events of hypertension, 2 events each of diarrhea and hypophosphatemia, and 1 pulmonary embolism. There were no Grade 4/5 AEs. Among 10 pts investigator-assessed confirmed ORR was 50% (1 CR, 4 PRs); 2 additional pts had unconfirmed PRs with only 1 tumor assessment at data cut-off.
Conclusions
C+A is well tolerated and shows encouraging anti-tumor activity in advanced RCC. C 40 mg QD + A 1200 mg Q3W was selected as the RD for expansion in multiple solid tumor cohorts including RCC.
Clinical trial identification
NCT03170960.
Legal entity responsible for the study
Exelixis, Inc.
Funding
Exelixis, Inc.
Editorial Acknowledgement
Disclosure
N. Agarwal: Consulting or advisory role: Pfizer, Novartis, Merck, Genentech, Eisai, Exelixis, Clovis, EMD Serono, BMS, AstraZeneca, Astellas. U. Vaishampayan: Honoraria: Astellas Pharma, Bayer, Bristol-Myers Squibb, Exelixis, Genentech, Janssen, Novartis, Pfizer, Sanofi; Consulting or advisory role: Astellas Pharma, Bayer, Bristol-Myers Squibb, Exelixis, Genentech/Roche, Novartis, Pfizer; Speakers' bureau: Astellas Pharma, Bayer, Bristol-Myers Squibb, Exelixis, Genentech/Roche, Novartis, Pfizer, Sanofi; Research funding: Astellas Pharma, Bristol-Myers Squibb, Exelixis, Novartis, Pfizer. M. Green, F. di Nucci: Employee: Genentech. P-Y. Chang: Employee of Exelixis Inc. C. Scheffold: Employee of and owns stock in Exelixis, Inc. S. Pal: Honoraria: Astellas Pharma, Medivation, Novartis; Consulting or advisory role: Aveo, Bristol-Myers Squibb, Exelixis, Genentech, Myriad Pharmaceuticals, Novartis, Pfizer; Research funding: Medivation.
Resources from the same session
4596 - Neoadjuvant Trial of nab-paclitaxel and Atezolizumab (Atezo), a PD-L1 inhibitor, in patients (pts) with chemo-insensitive Triple Negative Breast Cancer (TNBC)
Presenter: Jennifer Litton
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5349 - Prognostic implications of circulating tumor cells (CTCs) after neoadjuvant chemotherapy for triple negative breast cancer (TNBC)
Presenter: Carolyn Hall
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2568 - A prediction model for pathological complete response after neoadjuvant chemotherapy of HER2-negative breast cancer patients
Presenter: Lothar Häberle
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5413 - Evaluation of the MammaTyper® as a molecular predictor for pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) and outcome in patients with different breast cancer (BC) subtypes
Presenter: Peter A. Fasching
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2260 - Impact of clinical, morphologic and molecular characteristics on response to neoadjuvant systemic therapy (NAST) in metaplastic breast cancer (MpBC)
Presenter: Clinton Yam
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4722 - Evaluation of Human epidermal growth factor receptor 2 overexpression (HER2+) after administration of neoadjuvant treatment (NAT) and prognostic impact in breast cancer (BC)
Presenter: Duarte Machado
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4307 - Complete response (CR) to anthracycline-based chemotherapy using magnetic resonance imaging (MRI) predicts high rates of pathologic complete response (pCR) for triple negative breast cancer (TNBC) patients treated preoperatively with anthracycline and taxane-based regimens
Presenter: Maria Marin Alcala
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5018 - Immunomonitoring of triple negative breast cancer patients undergoing neoadjuvant therapy (GBG89, Geparnuevo trial)
Presenter: Barbara Seliger
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3203 - Impact of breast cancer subtype on survival after lumpectomy versus mastectomy for early stage invasive breast cancer
Presenter: YU-CHEN Tsai
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4887 - Survival Outcomes of Dose Dense Neoadjuvant and Adjuvant Chemotherapy in Triple-Negative Breast Cancer Patients – Indian Scenario
Presenter: TANVI Sood
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract